Less than 10% of people that would benefit from obesity jabs such as Wegovy can access them, caution the World Health Organization as it publishes its inaugural recommendations on the medications.
Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for broader and more equitable access to these injectable treatments.
Based on projections, over two billion are projected to be living with obesity by 2030 without intervention.
"Our new guidance affirms that excess weight is a lifelong illness that can be treated with comprehensive and continuous care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are significant hurdles to broad availability to the injections that can help people shift significant weight, says the agency.
Weight-Loss Drug Scarcity
Despite the present most optimistic scenario, the production of GLP-1 therapies would only suffice for around 100 million people – under 10% of eligible patients, per the health organization.
The advice urges governments and firms to expand access, by measures such as voluntary licensing.
The intellectual property rights on a key compound – the primary component of the drug Wegovy – is scheduled to end in a number of countries in 2026.
How Obesity Jabs Operate
The injections imitate a natural hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so individuals eat less.
Patients typically start to lose weight after several weeks of beginning the weekly injections.
Evidence indicates people may see weight return within a year of stopping the treatment, as their normal appetite return.
Being carrying excess weight increases your likelihood for developing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity impacts people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
